Home › Funds › Catalio Capital Management, LP › PTGX
Catalio Capital Management, LP position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
Catalio Capital Management, LP reported holding 106,799 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$13.1M, representing 2.46% of its reported portfolio and ranking #16 among its reported holdings. Catalio Capital Management, LP first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Catalio Capital Management, LP's PTGX position evolved
Catalio Capital Management, LP first disclosed a stake in PTGX in Q2 2026 at 106,799 shares (US$13.1M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 106.80K | $13.09M | New |
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 49 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.35M sh · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M sh · $620.40M · Q2 2026
- JOHNSON & JOHNSON 2.45M sh · $300.22M · Q2 2026
- Woodline Partners LP 1.41M sh · $173.35M · Q2 2026
- PERCEPTIVE ADVISORS LLC 981.88K sh · $120.36M · Q2 2026
- ADAR1 Capital Management, LLC 960.86K sh · $117.78M · Q2 2026
- Hood River Capital Management LLC 882.74K sh · $108.21M · Q2 2026
- 683 Capital Management, LLC 290.00K sh · $35.55M · Q2 2026
- Eagle Health Investments LP 248.32K sh · $30.44M · Q2 2026
More on Catalio Capital Management, LP
FAQ
How long has Catalio Capital Management, LP held PTGX?
Catalio Capital Management, LP has disclosed PTGX holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Catalio Capital Management, LP's current position in PTGX?
As of Q2 2026, Catalio Capital Management, LP holds 106.80K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $13.09M, representing 2.46% of its reported portfolio and ranking #16.
Has Catalio Capital Management, LP been buying or selling PTGX?
In the latest 13F filing (Q2 2026), Catalio Capital Management, LP newly opened its position in PTGX.
Which other funds hold PTGX?
Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.